In this study, CRISPR/Cas9‐edited Pd‐l1KO TDEV‐fusogenic anthracycline doxorubicin (DOX) liposomes with high drug encapsulation (97%) are fabricated, which homologously deliver DOX to breast cancer cells to intensify the immunogenic response and induce PD‐L1 overexpression in the tumor. This evidence concerns the gene CD274 and breast cancer.